- Conditions
- Basal Cell Carcinoma
- Interventions
- LDE225
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 230 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2018
- U.S. locations
- 22
- States / cities
- Fayetteville, Arkansas • Los Angeles, California • Stanford, California + 17 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1009–1032
of 2,839
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Breast Cancer
- Interventions
- Enzastaurin, Bevacizumab, Paclitaxel, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 7
- States / cities
- Newark, Delaware • Galesburg, Illinois • Fort Wayne, Indiana + 4 more
- Conditions
- Metastatic Cancer, Metastatic Lung Cancer, Metastatic Breast Cancer, Metastatic Tumor, Metastatic Tumor of Bone, Metastatic Tumor to the Spine, Spine Metastases, Metastasis
- Interventions
- SBRT to the spine
- Radiation
- Lead sponsor
- Stony Brook University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Stony Brook, New York
- Conditions
- Breast Cancer, Hot Flashes
- Interventions
- St. John's Wort
- Drug
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 19
- States / cities
- Newark, Delaware • Washington D.C., District of Columbia • Miami, Florida + 16 more
- Conditions
- Melanoma (Skin)
- Interventions
- everolimus
- Drug
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2010
- U.S. locations
- 94
- States / cities
- Scottsdale, Arizona • Jacksonville, Florida • Aurora, Illinois + 60 more
- Conditions
- Melanoma (Skin)
- Interventions
- adenovirus RSV-TK, ganciclovir
- Biological · Drug
- Lead sponsor
- National Human Genome Research Institute (NHGRI)
- NIH
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 3
- States / cities
- Bethesda, Maryland • Houston, Texas
- Conditions
- Recurrent Breast Cancer, Stage IIIB Breast Cancer, Stage IV Breast Cancer
- Interventions
- suramin, paclitaxel, pharmacological study
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2008
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Metastatic Breast Cancer
- Interventions
- Ad-RTS-hIL-12, Veledimex
- Biological · Drug
- Lead sponsor
- Alaunos Therapeutics
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Advanced or Metastatic Solid Tumors, Advanced or Metastatic Breast Cancer
- Interventions
- Azacitidine (Vidaza), Nab-paclitaxel (Abraxane)
- Drug
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2015
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Cancer
- Interventions
- mycophenolate mofetil, placebo
- Drug
- Lead sponsor
- Martin, Paul
- Other
- Eligibility
- 4 Years and older
- Enrollment
- 151 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 15
- States / cities
- Duarte, California • Stanford, California • Gainesville, Florida + 11 more
- Conditions
- Cervical Cancer, Microsatellite Instability (MSI)-High Endometrial Cancer, Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ]), Esophageal Cancer, Hepatocellular Carcinoma, Melanoma (Uveal Melanoma Excluded), Merkel Cell Carcinoma, Mesothelioma, MSI-high Colorectal Cancer, Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, Squamous Cell Carcinoma of the Head and Neck (SCCHN), Small Cell Lung Cancer (SCLC), Renal Cell Carcinoma (RCC), Triple-negative Breast Cancer, Urothelial Carcinoma, Diffuse Large B-cell Lymphoma
- Interventions
- INCAGN02385
- Biological
- Lead sponsor
- Incyte Biosciences International Sàrl
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Hackensack, New Jersey • Huntersville, North Carolina + 1 more
- Conditions
- Metastatic Breast Cancer, Gastrointestinal Tumors
- Interventions
- Sorafenib, Capecitabine
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Melanoma, Ocular, Melanoma, Cutaneous, Metastatic Melanoma, Melanoma, Mucosal, Liver Metastases
- Interventions
- Ipilimumab, Nivolumab, Stereotactic Body Radiation Therapy
- Drug · Procedure
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Castration-Resistant Prostate Cancer (CRPC), Colorectal Cancer, NSCLC (Non-small Cell Lung Cancer), Ovarian Cancer, Cervical Cancer, Endometrial Cancer, TNBC, Triple Negative Breast Cancer, Small Cell Lung Cancer (SCLC ), Head &Amp; Neck Squamous Cell Carcinoma (HNSCC), Esophageal Squamous Cell Carcinoma (ESCC), Sarcoma
- Interventions
- 177Lu-BetaBart, BetaBart + unlabeled BetaBart
- Drug
- Lead sponsor
- Radiopharm Theranostics, Ltd
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 5
- States / cities
- Dothan, Alabama • Grand Rapids, Michigan • Omaha, Nebraska + 1 more
- Conditions
- Small Cell Lung Cancer and Breast Cancer
- Interventions
- Satoreotide tetraxetan, Satoreotide trizoxetan
- Drug
- Lead sponsor
- Ipsen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Pancreatic Cancer, Thyroid Cancer, Lung Cancer, Esophageal Cancer, Thymus Cancer, Colon Cancer, Rectal Cancer, Gastrointestinal Stromal Tumors, Anal Cancer, Bile Duct Cancer, Duodenal Cancer, Gallbladder Cancer, Gastric Cancer, Liver Cancer, Small Intestine Cancer, Peritoneal Surface Malignancies, Familial Adenomatous Polyposis, Lynch Syndrome, Bladder Cancer, Kidney Cancer, Penile Cancer, Prostate Cancer, Testicular Cancer, Ureter Cancer, Urethral Cancer, Hypopharyngeal Cancer, Laryngeal Cancer, Lip Cancer, Oral Cavity Cancer, Nasopharyngeal Cancer, Oropharyngeal Cancer, Paranasal Sinus Cancer, Nasal Cavity Cancer, Salivary Gland Cancer, Skin Cancer, Central Nervous System Tumor, Central Nervous System Cancer, Mesothelioma, Breast Cancer, Leukemia, Melanoma, Sarcoma, Unknown Primary Tumor, Multiple Myeloma, Ovarian Cancer, Endometrial Cancer, Vaginal Cancer, Neuroendocrine Tumors, Plasma Cell Dyscrasia, Healthy Control
- Interventions
- Not listed
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 19 Years to 110 Years
- Enrollment
- 999,999 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2099
- U.S. locations
- 42
- States / cities
- Greenwood Village, Colorado • Manchester, Connecticut • Daytona Beach, Florida + 34 more
- Conditions
- Clinical Stage IV Cutaneous Melanoma AJCC v8, Melanoma of Unknown Primary, Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Metastatic Mucosal Melanoma, Metastatic Ocular Melanoma, Pathologic Stage IV Cutaneous Melanoma AJCC v8
- Interventions
- Ipilimumab, Nivolumab, Pembrolizumab, Stereotactic Radiosurgery, Tumor Treating Fields Therapy
- Biological · Radiation · Procedure
- Lead sponsor
- Emory University
- Other
- Eligibility
- 22 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Estrogen Receptor-positive (ER+)/Human Epidermal Growth Factor Receptor (HER2)-Negative Locally Advanced or Metastatic Breast Cancer
- Interventions
- Venetoclax, Fulvestrant
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 21
- States / cities
- Phoenix, Arizona • Springdale, Arkansas • La Jolla, California + 18 more
- Conditions
- Metastatic Breast Cancer, Lung Metastases, Liver Metastases
- Interventions
- MEDI6469
- Biological
- Lead sponsor
- Providence Health & Services
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8, Recurrent Breast Carcinoma, Refractory Breast Carcinoma
- Interventions
- Cyclophosphamide, Allogeneic GM-CSF-secreting Breast Cancer Vaccine SV-BR-1-GM, Pembrolizumab, Recombinant Interferon Alpha 2b-like Protein, Questionnaire Administration, Quality of Life Assessment
- Drug · Biological · Other
- Lead sponsor
- Thomas Jefferson University
- Other
- Eligibility
- 18 Years and older · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Metastatic Breast Cancer
- Interventions
- Enobosarm & Abemaciclib Combo, non-steroidal AI, or steroidal AI (exemestane with or without everolimus) or Fulvestrant
- Drug
- Lead sponsor
- Veru Inc.
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 30
- States / cities
- Chandler, Arizona • Gilbert, Arizona • Tucson, Arizona + 26 more
- Conditions
- Breast Cancer
- Interventions
- Poziotinib
- Drug
- Lead sponsor
- Spectrum Pharmaceuticals, Inc
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 35
- States / cities
- Huntsville, Alabama • Anaheim, California • Greenbrae, California + 31 more
- Conditions
- Breast Cancer
- Interventions
- BYL-719 (alpelisib), Nab-paclitaxel
- Drug
- Lead sponsor
- Priyanka Sharma
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2022
- U.S. locations
- 4
- States / cities
- Kansas City, Kansas • Overland Park, Kansas • Lee's Summit, Missouri + 1 more
- Conditions
- Breast Cancer
- Interventions
- filgrastim, CMF regimen, carboplatin, cyclophosphamide, docetaxel, doxorubicin hydrochloride, etoposide, fluorouracil, ifosfamide, methotrexate, thiotepa, peripheral blood stem cell transplantation
- Biological · Drug · Procedure
- Lead sponsor
- Herbert Irving Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years to 59 Years · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 1
- States / cities
- New York, New York